Overview

This trial is active, not recruiting.

Condition rett syndrome with proven mecp2 mutation
Treatment biological markers and evaluation of the mineral density at the lumber spine using dexa
Sponsor Assistance Publique - Hôpitaux de Paris
Start date December 2009
End date September 2016
Trial size 98 participants
Trial identifier NCT02110797, P071230

Summary

Based on our clinical observations, many girls with RETT syndrome, a severe neuro-developmental encephalopathy, suffer from osteoporosis which can appear at a very early age (before age 10) and can lead to fractures, pain and a limitation in mobility. Few epidemiological studies have estimated the frequency of osteoporosis in girls with RETT syndrome and showed that they are more exposed then children with other neuro-developmental diseases with a same degree of neurological handicap. However, the mechanisms that lead to early osteoporosis in RETT syndrome remain unknown. Mutations in the MECP2 gene are found in 95% of RETT patients and preliminary experimental studies have shown that this can lead to abnormal expression of the gene that codes for osteoprotegerin, a protein implicated in bone remodelling by interacting with RANK-ligand.

In order to identify risk factors of osteoporosis in RETT syndrome and to understand the pathophysiological mechanisms the study protocol includes:

1. Clinical evaluation of bone health (history of bone fractures, pain, nutritional status, pubertal stage, daily caloric/calcium intake, anti-epileptic drugs, walking ability, vitamin D satus)

2. evaluation of the mineral density at the lumber spine using DEXA

3. measuring concentrations of osteoprotegerin and RANK-ligand

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Intervention model single group assignment
Masking open label
Primary purpose diagnostic
Arm
(Other)
biological markers and evaluation of the mineral density at the lumber spine using dexa

Primary Outcomes

Measure
osteoporosis in RETT patients
time frame: Day 0

Secondary Outcomes

Measure
Biological Mechanisms of osteoporosis
time frame: Day 0

Eligibility Criteria

Female participants from 5 years up to 45 years old.

Inclusion Criteria: - RETT syndrome - MECP2 mutation Exclusion Criteria: - no identified MECP2 mutation - history of drugs that interfere with bone metabolism

Additional Information

Official title Osteoporosis in RETT Syndrome. Understanding the Mechanisms and Identification of Biomarkers.
Principal investigator Agnès Linglart, MD, PhD
Description Based on our clinical observations, many girls with RETT syndrome, a severe neuro-developmental encephalopathy, suffer from osteoporosis which can appear at a very early age (before age 10) and can lead to fractures, pain and a limitation in mobility. Few epidemiological studies have estimated the frequency of osteoporosis in girls with RETT syndrome and showed that they are more exposed to osteoporosis then children with other neuro-developmental diseases with a same degree of neurological handicap. However, the mechanisms that lead to early osteoporosis in RETT syndrome remain unknown. Mutations in the MECP2 gene are found in 95% of RETT patients. Preliminary experimental studies on the transcriptional consequences of MECP2 mutations showed that the expression of 13 genes were significantly dysregulated and one of them is the gene that codes for osteoprotegerin, a soluble receptor that binds to RANK-ligand. RANK-ligand is an osteoclastic differentiation factor expressed by osteoblasts. In order to identify risk factors of osteoporosis in RETT syndrome and to understand the pathophysiological mechanisms the study protocol includes: 1. Clinical evaluation of bone health (history of bone fractures, pain, nutritional status, pubertal stage, daily caloric/calcium intake, anti-epileptic drugs, walking ability, vitamin D status) 2. evaluation of the mineral density at the lumber spine using DEXA 3. measuring concentrations of osteoprotegerin and RANK-ligand
Trial information was received from ClinicalTrials.gov and was last updated in July 2016.
Information provided to ClinicalTrials.gov by Assistance Publique - Hôpitaux de Paris.